Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 6/20 | 0.45 |
| ▸ | RARA | P10276 | 5/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 4/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177361 | 0.91 | ALDH1A1 (0.57) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL8293242 | 0.78 | RARA (0.48) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL9141312 | 0.77 | ALDH1A1 (0.64) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL8699677 | 0.77 | RARA (0.44) | ALDH1A1MAPTKMT2AHPGDRARB | |
| SCHEMBL17675356 | 0.77 | RARB (0.44) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL8776409 | 0.77 | RARB (0.52) | ALDH1A1RARBRARASMN1; SMN2RARG | |
| SCHEMBL7665323 | 0.76 | RARA (0.50) | ALDH1A1RARBRARASMN1; SMN2RARG | |
| SCHEMBL7665318 | 0.76 | RARA (0.50) | ALDH1A1RARBRARASMN1; SMN2RARG | |
| SCHEMBL7665311 | 0.76 | RARA (0.50) | ALDH1A1RARBRARASMN1; SMN2RARG | |
| SCHEMBL3838099 | 0.75 | RARB (0.57) | ALDH1A1RARBRARASMN1; SMN2RARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559709-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | Eisai Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-0838453-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| US-6884808-B2 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6630463-B2 | Such as 4-(4-(2-(2-(5,6,7,8-tetrahydro-5,5,8,8 -tetramethylquinoxalyl))pyrrolyl))benzoic acid; for treatment of acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-10-07 | — | — | US | disclosed |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6541474-B2 | Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-08-01 | — | — | US | disclosed |
| US-6420363-B1 | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-03-14 | — | — | US | disclosed |
| US-6329402-B1 | FOR THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA | EISAI CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6291508-B1 | POTENT ABILITY TO BIND TO RETINOIC ACID RECEPTORS THUS USEFUL IN TREATING PSORIASIS AND RHEUMATOID ARTHRITIS. | EISAI CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6133283-A | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6030964-A | BINDS TO RETINOIC ACID RECEPTORS AND USEFUL FOR TREATING PSORIASIS, AUTOIMMUNE DISEASES, TUMORS, RHEUMATOID ARTHRITIS AND FOR INDUCING IMMUNOSUPPRESSION IN ORGAN TRANSPLANTATION | EISAI CO., LTD. (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5977125-A | Mono-or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5977108-A | LEUKEMIA | EISAI CO., LTD (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0838453-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0790228-A1 | MONO- OR POLYENIC CARBOXYLIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | ALDH1A1 44/4885MAPT 4687/4885MEN1 2439/4885 |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | ALDH1A1 37/4885MAPT 4651/4885MEN1 2431/4885 |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | ALDH1A1 37/4885MAPT 4651/4885MEN1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.